EP-1356 Targeted therapy with or without Radiotherapy in EGFR/ALK mutant NSCLC with Brain Metastases
نویسندگان
چکیده
منابع مشابه
Whole brain radiotherapy in patients with NSCLC and brain metastases
1960 www.thelancet.com Vol 388 October 22, 2016 Radiation oncologists are often challenged because of the paucity of randomised trials supporting their clinical practice. In terms of brain metastases treatment, it should be emphasised that there have been fi ve randomised trials assessing whole brain radiotherapy (WBRT): four studies assessing stereotactic radio therapy with or without WBRT for...
متن کاملRandomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases
BACKGROUND Median survival of non-small cell lung cancer (NSCLC) patients with brain metastases is poor. We examined concurrent erlotinib and whole brain radiotherapy (WBRT) followed by maintenance erlotinib in patients with untreated brain metastases, given the potential radiosensitizing properties of erlotinib and its direct effect on brain metastases and systemic activity. METHODS Eighty N...
متن کاملWhole-brain radiotherapy for NSCLC patients with multiple brain metastases – an update
Non-small cell lung cancer (NSCLC) constitutes approximately 85% of all lung cancers, with the majority of patients having advanced disease at presentation. Between 10-20% present with brain metastases (BM) and up to 40% of patients will develop BM. The overall median survival is reported to average three to four months if treated with whole brain radiotherapy (WBRT) alone. Management of BM pat...
متن کاملPhase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma
The aim of this paper is to explore the efficacy of whole brain radiotherapy (WBRT) versus WBRT concurrent with erlotinib in patients with multiple brain metastases of lung adenocarcinoma. WBRT was administered at 30Gy/10f in both arms. In the combination arm, 150 mg erlotinib was given each day, starting the first day of radiotherapy and continuing for 1 month following the end of radiotherapy...
متن کاملGefitinib Alone or with Whole Brain Radiotherapy for Patients with Brain Metastasis from NSCLC
Brain metastases (BM) are found in approximately 20-40% of all patients with non-small-cell lung cancer (NSCLC), especially in adenocarcinoma (Olak 1999; Yawn et al., 2003). The outcomes of BM from NSCLC are very poor with few effective treatment options. The median overall survival time (OS) of patients without treatment is less than 3 months (Nussbaum et al., 1996). Whole brain radiotherapy (...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Radiotherapy and Oncology
سال: 2019
ISSN: 0167-8140
DOI: 10.1016/s0167-8140(19)31776-1